Compare
Instil Bio, Inc. vs Neumora Therapeutics, Inc. vs Compass Therapeutics, Inc. vs enGene Therapeutics Inc.
| Latest fiscal year | Instil Bio, Inc. TIL | Neumora Therapeutics, Inc. NMRA | Compass Therapeutics, Inc. CMPX | enGene Therapeutics Inc. ENGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-10-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$71.37M | -$236.93M | -$66.49M | -$117.30M |
| EPS (Diluted) | -$10.70 | -$1.45 | n/a | $2.29 |
| Operating cash flow | -$36.62M | -$206.44M | -$49.14M | -$99.24M |
| Free cash flow | n/a | n/a | -$49.17M | -$100.72M |
| Cash & equivalents | $6.64M | $182.53M | $30.64M | $50.15M |
| Total assets | $203.52M | $191.05M | $219.59M | $221.47M |
| Total liabilities | $89.66M | $87.18M | $22.80M | $53.76M |
| Shareholders' equity | $113.87M | $103.87M | $196.79M | $167.71M |
| Return on year-end equity | -62.7% | -228.1% | -33.8% | -69.9% |
| Shares outstanding | 6.78M | 174.26M | 178.32M | 52.02M |
Revenue, most recent five fiscal years
| Fiscal year | Instil Bio, Inc. | Neumora Therapeutics, Inc. | Compass Therapeutics, Inc. | enGene Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2021-12-31 | n/a | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | $138.0K Ended 2020-12-31 | n/a | $850.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |